Products, Partners & Public Health: Commercializing New Products From NIH 

Event description

The focal point for U.S. government investment in innovative healthcare research and development has been the National Institutes of Health (NIH). 

The intramural research program itself at the NIH has led to a huge variety of novel basic and clinical research discoveries – all of which require commercial partners in order to develop them into products for hospital, physician or patient use. 

With over half of new NIH license agreements granted to small firms and over 1000 products (including 48 FDA-approved drugs and vaccines) launched by NIH licensees, working with the NIH cannot be overlooked as part of any long-term growth strategy for biomedical firms.